Skip to main content
TCDAinactive

Tricida, Inc.

Biopharma developer (SEC filing verified)·Phase 3
MetabolicNephrology

TCDA evidence brief

What we can confirm

BioSniper Score:
5.9 / 10
Lead Asset:
veverimer (Phase 3)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 5.9 / 10 · Lead Asset: veverimer (Phase 3)
BioSniper AIPage context preserved

Prepared research question

What matters most for TCDA—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

5.9/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

veverimer (Phase 3)

Next Catalyst

—

Tracking 1 pipeline candidate for Tricida, Inc..

Run Tricida, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Tricida, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is Tricida, Inc.'s lead drug candidate?

Tricida, Inc.'s most advanced tracked candidate is veverimer (Phase 3) for metabolic acidosis in patients with chronic kidney disease (CKD).

What therapeutic areas does Tricida, Inc. focus on?

Tricida, Inc. develops therapies across Metabolic, Nephrology.

923 active companies304,861 SEC filings22,725 clinical trials
Citation log window (7 days): 13,363 recorded LLM calls; 0 block events, 0 warning events. These counts do not measure factual accuracy or research quality.Computed at
How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.